LBS-009

N/A

Report date: 2024/06/27 11:03:48
NME

Base Information

Drug NameLBS-009
Drug Alias NameLBS-009
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionRetinol-binding protein 4 inhibitors
TargetsRetinol-binding protein 4
Therapy Area/IndicationsDiabetes Mellitus, Type 2Metabolic Dysfunction-Associated Steatotic Liver Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesLin Bioscience IncBelite Bio Inc
China Registration ClassN/A

Develop Information

Active CompaniesBelite Bio Inc
Inactive CompaniesN/A
Active IndicationsDiabetes Mellitus, Type 2Metabolic Dysfunction-Associated Steatotic Liver Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A